199.86

4.78% 9.12

Pre-market: 201.00 1.14 +0.57%

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $199.86, with a volume of 4.06M. It is up +4.78% in the last 24 hours and down -5.54% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Previous Close:

$190.74

Open:

$190.15

24h Volume:

4.06M

Relative Volume:

1.83

Market Cap:

$42.84B

Revenue:

$742.00K

Net Income/Loss:

$-1.37B

P/E Ratio:

-28.26

EPS:

-7.0731

Net Cash Flow:

$-1.07B

1W Performance:

+1.48%

1M Performance:

-5.54%

6M Performance:

+109.23%

1Y Performance:

+359.03%

1-Day Range:

$189.84

$201.28

1-Week Range:

$188.18

$201.28

52-Week Range:

$42.18

$224.31

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

650-481-6801

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

883

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

RVMD's Discussions on Twitter

Compare RVMD vs VRTX, REGN, MRNA, ARGX

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Feb-27-26	Resumed	UBS	Buy
Nov-18-25	Initiated	Wolfe Research	Outperform
Nov-03-25	Initiated	RBC Capital Mkts	Outperform
Oct-21-25	Initiated	Mizuho	Outperform
Oct-16-25	Resumed	Stifel	Buy
Sep-12-25	Resumed	Raymond James	Strong Buy
Sep-05-25	Initiated	Truist	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Aug-15-25	Initiated	Wells Fargo	Overweight
Jul-15-25	Initiated	Goldman	Buy
Jul-16-24	Reiterated	Needham	Buy
Jul-12-24	Initiated	Barclays	Overweight
Jul-08-24	Initiated	Jefferies	Buy
Apr-12-24	Reiterated	Needham	Buy
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-11-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

03:16 AM

Form 144 Revolution Medicines For: 25 September By Investing.com - Investing.com UK

03:16 AM

Sep 24, 2026

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? - finance.yahoo.com

Sep 24, 2026

Revolution Medicines director Elizabeth Anderson sells $1.96m in stock - Investing.com

Sep 24, 2026

Form 4 Revolution Medicines Inc For: 24 September By Investing.com - Investing.com India

Sep 24, 2026

Revolution Medicines Gains as New Buy Rating Adds to Recent Regulatory Momentum - quiverquant.com

Sep 24, 2026

After three earlier sales, an officer proposes selling 587 more Revolution Medicines (RVMD) shares. - Stock Titan

Sep 24, 2026

Goldman Sachs Reinitiates Buy on RVMD with $267 Target Amid Biot - GuruFocus

Sep 24, 2026

Sep 23, 2026

How (RVMD) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 23, 2026

Sep 22, 2026

Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? - finance.yahoo.com

Sep 22, 2026

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com

Sep 22, 2026

Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Australia

Sep 22, 2026

Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE - finance.yahoo.com

Sep 22, 2026

Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan

Sep 22, 2026

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today - Benzinga

Sep 22, 2026

AIM ImmunoTech Highlights Ampligen’s Potential Role in the - GlobeNewswire

Sep 22, 2026

Illinois grew the science behind a breakthrough cancer drug — but couldn’t hold onto the company - Crain's Chicago Business

Sep 22, 2026

Sep 21, 2026

RVMD Maintained by B of A Securities -- Price Target Raised to $265 - GuruFocus

Sep 21, 2026

Client Revolution Medicines Secures 672,000-Square-Foot Redwood City Lease in former Google Space - Procopio

Sep 21, 2026